5 results match your criteria: "Papageorgiou Hospital and.[Affiliation]"
Relationship of 24-h ambulatory blood pressure variability with micro and macrovascular parameters and hypertension status.
J Hypertens
January 2023
3rd Department of Internal Medicine, Papageorgiou Hospital and.
Objectives: Increased blood pressure variability (BPV) has been associated with an increased risk of subclinical organ damage and cardiovascular events, independently of elevated average BP values. We aimed to investigate the association of BPV indices with micro- and macrovascular parameters, some of them not previously studied.
Methods: We evaluated 344 individuals (233 never-treated/newly diagnosed hypertensive and 111 normotensive individuals).
The use of urinary biomarkers in the diagnosis of overactive bladder in female patients. A systematic review and meta-analysis.
Int Urogynecol J
December 2021
1st Department of Obstetrics and Gynecology, "Papageorgiou" General Hospital, Aristotle University of Thessaloniki, Ring Road, Nea Efkarpia, 56403, Thessaloniki, Greece.
Article Synopsis
- - The study reviews the link between urinary concentrations of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and other proteins in relation to overactive bladder (OAB) syndrome in women, aiming to explore their potential as biomarkers for the condition.
- - A systematic review identified twelve studies involving 581 female OAB patients and 394 controls, finding that levels of urinary NGF, NGF/Cr, and BDNF/Cr ratios were significantly higher in OAB patients compared to healthy individuals.
- - The conclusion suggests that uNGF, NGF/Cr, and BDNF/Cr ratios show promise for assessing OAB in women, but further research is needed to clarify their
Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry.
J Glob Oncol
September 2018
Hideyuki Akaza, The University of Tokyo, Tokyo, Japan; Giuseppe Procopio, Istituto Nazionale Tumori; Sergio Fava, Ospedale Civile di Legnano, Milan; Gaetano Facchini, Istituto Nazionale Tumori Istituto di Ricerca e Cura a Carattere Scientifico Fondazione Pascale, Naples, Italy; Choosak Pripatnanont, Prince of Songkla University, Songkla, Thailand; Duncan Wheatley, Royal Cornwall Hospital, Truro; Mohammad Butt, Castle Hill Hospital, Hull, United Kingdom; Kwong Chuen Leung, Queen Elizabeth Hospital, Hong Kong, Special Administrative Region, People's Republic of China; Alberto Silva, Instituto de Cancer do Ceará, Fortaleza, Brazil; Liliana Castillo, Hospital Oncológico Miguel Pérez Carreño, Valencia, Venezuela; Vasilios Karavasilis, Papageorgiou Hospital and Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece; Ayse Ӧzatılgan, Sanofi, Cambridge, MA; Simon Hitier, Sanofi, Chilly-Mazarin; Evelyne B. Ecstein-Fraisse, Sanofi, Paris, France; and Mustafa Ӧzgüroḡlu, Istanbul University, Istanbul, Turkey.
Purpose: There is a major clinical need to devise an optimal treatment sequence for the multiple therapy options available for patients with metastatic castration-resistant prostate cancer (mCRPC). In the absence of prospective clinical trials, sequencing information can be derived from large, real-world registry studies.
Patients And Methods: PROXIMA (Treatment Patterns in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy) is a large, global, prospective registry study evaluating real-world treatment patterns of patients with mCRPC who experience disease progression during or after docetaxel therapy.
European consensus on the concepts and measurement of the pathophysiological neuromuscular responses to passive muscle stretch.
Eur J Neurol
July 2017
Department of Rehabilitation Medicine, VU University Medical Center, Amsterdam, The Netherlands.
Article Synopsis
- A consensus reached by 37 experts from 12 European countries aimed to clarify the terminology related to neuromuscular responses during passive muscle stretch in central neurological disorders.
- The study introduced the term "hyper-resistance" to describe impaired responses, distinguishing between non-neural (tissue-related) and neural (CNS-related) contributions to this phenomenon.
- A new conceptual framework for assessing hyper-resistance was established, suggesting the need for objective measurements to enhance communication among clinicians and improve treatment strategies.
Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report.
Eur Urol
January 2009
2nd Department of Urology, Papageorgiou Hospital and Centre for Study of Continence and Pelvic Floor Dysfunctions, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Context: The increasing body of evidence and number of potential indications for the use of botulinum neurotoxins (BoNTs) in the lower urinary tract (LUT) underlines the pressing need for evidence-based guidelines.
Objective: A European expert panel consensus conference was convened with the main aim of evaluating the evidence and clinical considerations for the use of BoNTs in the treatment of urologic and pelvic-floor disorders and to propose relevant recommendations.
Evidence Acquisition: The quality of evidence from fully published English-language literature in the PubMed and EMBASE databases was assessed using the European Association of Urology (EAU) levels of evidence (LoE).